1621681-63-7: Cabozantinib N-Oxide

1621681-63-7: Cabozantinib N-Oxide

It is one of impurity present in Cabozantinib, Cabozantinib is a tyrosine kinase inhibitor, which inhibits the activity of c-MET vascular endothelial growth factor receptor and other tyrosine kinases, thereby leading to reduced tumor angiogenesis motility and invasiveness. which is used in the treatment of progressive, metastatic medullary thyroid cancer, also indicated for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma.

Additional information on CAS 1621681-63-7

Catalogue No.

VE007672
CAS No.

1621681-63-7
Molecular Formula

C28H24FN3O6
Molecular Weight

517.51 g/mol
Parent drug

Cabozantinib
IUPAC Name

N-[4-[(6, 7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N’-(4-fluorophenyl)-1, 1-cyclopropanedicarboxamide
Synonyms

N/A
References

Schmidinger, M., & Danesi, R. (2017). Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. The Oncologist, 23(3), 306–315. https://doi.org/10.1634/theoncologist.2017-0335
Status

In-stock

Other products related to cabozantinib

Request a quote

1621681-63-7: Cabozantinib N-Oxide

1621681-63-7: Cabozantinib N-Oxide
Catalogue No.

VE007672
CAS No.

1621681-63-7
Molecular Formula

C28H24FN3O6
Molecular Weight

517.51 g/mol
Parent drug

Cabozantinib
IUPAC Name

N-[4-[(6, 7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N’-(4-fluorophenyl)-1, 1-cyclopropanedicarboxamide
Synonyms

N/A
References

Schmidinger, M., & Danesi, R. (2017). Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. The Oncologist, 23(3), 306–315. https://doi.org/10.1634/theoncologist.2017-0335
Status

In-stock
ListName

Cabozantinib N-Oxide
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url